CUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE

The commercial-business sale drove quarterly profit, while continuing operations remained loss-making as Cumberland shifted toward drug development.

Rhea-AI Summary

Cumberland Pharmaceuticals (CPIX) reported third-quarter 2026 net income of $77.8 million, including a gain from selling its commercial business to Apotex Health. The transaction closed July 1, 2026, providing $100 million at closing and shifting Cumberland toward drug development. Quarterly revenue was $2,156,356 versus $171,821 a year earlier; the continuing-operations loss narrowed to $1,122,071 from $2,730,638. Cash totaled $80,581,021 at September 30.

Cumberland plans to submit an application for FDA approval of ifetroban for Duchenne muscular dystrophy heart disease; the FDA granted rolling review, allowing sections to be reviewed before the full application is filed. Phase 2 data showed a 5.4 percentage point improvement in heart pumping function versus a combined control group. Its systemic sclerosis trial reported no serious adverse events assessed as treatment-related; further development awaits additional evaluations.

21 points · 1 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 7 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointApotex Health transaction closed July 1, 2026, providing $100 million at closing. 1.2× market cap
• Moderate pointQ3 net income reached $77,777,752, versus a $1,949,046 loss a year earlier, including the disposal gain.
• Moderate pointQ3 revenue increased to $2,156,356 from $171,821 a year earlier.
• Moderate pointQ3 continuing-operations loss narrowed to $1,122,071 from $2,730,638 a year earlier.
• Moderate pointLine-of-credit payments totaled $5,240,733 over nine months, leaving no balance at September 30, 2026. 6.5% of market cap
• Moderate point. Forward-looking: it has not happened yet and may not happen.Cumberland plans an ifetroban approval application for DMD heart disease; FDA granted rolling review.
• Moderate pointDMD Phase 2 high-dose treatment improved heart pumping function by 5.4 percentage points versus combined controls, p=0.002.

14 minor points

• Minor pointQ3 diluted earnings per share were $5.07, versus a $0.13 loss a year earlier.
• Minor pointQ3 general and administrative expenses decreased to $2,182,285 from $2,376,284 a year earlier.
• Minor pointQ3 interest income increased to $822,886 from $131,583 a year earlier.
• Minor pointNine-month revenue increased to $2,486,665 from $719,247 a year earlier.
• Minor pointNine-month net income reached $70,216,272, versus a $1,436,069 loss a year earlier.
• Minor pointNine-month continuing-operations loss narrowed to $7,159,927 from $8,358,416 a year earlier.
• Minor pointCash increased to $80,581,021 at September 30, 2026, from $11,444,693 at December 31, 2025.
• Minor pointShareholders' equity increased to $72,505,965 from $24,880,322 at December 31, 2025.
• Minor pointNine-month common-share repurchases returned $318,820 to shareholders.
• Minor pointDMD treatment through up to 36 months showed no treatment-related serious adverse events or new safety concerns.
• Minor pointIfetroban holds Orphan Drug, Rare Pediatric Disease and Fast Track designations for DMD.
• Minor pointCumberland has secured patents protecting ifetroban for the DMD heart disease indication.
• Minor pointSystemic sclerosis trial reported no serious adverse events assessed as drug-related during its 12-month treatment period.
• Minor point. Forward-looking: it has not happened yet and may not happen.Cumberland plans FDA report submission, biomarker studies and cardiac imaging evaluations following the systemic sclerosis trial.

Negative

• Moderate pointQ3 transition-services costs totaled $1,062,266, versus none a year earlier. 1.3% of market cap
• Moderate pointNine-month operating cash flow turned to $942,253 used, versus $4,929,497 provided a year earlier.
• Minor pointQ3 discontinued operations lost $1,725,098 before the disposal gain and related tax, versus $781,592 income a year earlier.
• Minor pointNine-month discontinued operations lost $3,248,722 before the disposal gain and related tax, versus $6,922,347 income a year earlier.
• Minor pointQ3 research and development expense rose to $841,162 from $646,473 a year earlier.

2 minor points

• Minor pointNine-month research and development expense rose to $2,379,170 from $2,178,866 a year earlier.
• Minor point. Forward-looking: it has not happened yet and may not happen.Further systemic sclerosis development depends on additional biomarker and cardiac imaging findings.

News Explained

The release’s cash-flow statement records a $22,479,497 cash dividend paid for the nine months ended September 30, 2026, adding a completed distribution to shareholders alongside the sale proceeds received at closing.

Key Figures

Transaction proceeds: $100 million LVEF improvement: 5.4 percentage points P-value: p=0.002 +5 more

Transaction proceeds

$100 million

Strategic Transaction; proceeds received at closing

LVEF improvement

5.4 percentage points

Phase 2 FIGHT DMD high-dose group versus combined control group

P-value

p=0.002

Phase 2 FIGHT DMD high-dose group comparison

Safety database

More than 1,400 subjects across approximately 30 clinical studies

Database to be included in the NDA submission

DMD treatment duration

Up to 36 months

Phase 2 trial and open-label extension; no treatment-related serious adverse events reported

SSc treatment period

12 months

Phase 2a ASSIST-SSc trial; no related serious adverse event reported

Net income

$77.8 million

Q3 2026; included gain on divestiture

Cash and cash equivalents

$80.6 million

As of September 30, 2026

Previous Earnings Reports

1 past event · Latest: Aug 04

Same Type 1 event

1. Aug 04

   Q2 earnings

   24h Move

   -2.8%

   Apotex transaction closed for $100 million as Cumberland shifted toward development programs.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nda, rolling review, left ventricular ejection fraction, propensity score-matched

4 terms

nda regulatory

"submit a New Drug Application ("NDA") to the U.S. Food and Drug Administration"

An NDA, or nondisclosure agreement, is a legal contract that keeps certain information private between parties. It’s like a promise not to share sensitive details, helping protect business ideas, strategies, or data from being leaked or used without permission. For investors, NDAs help ensure that confidential information remains secure, enabling trust and open communication during business discussions.

rolling review regulatory

"The FDA granted Cumberland's request for a rolling review"

A rolling review is a regulatory process where health authorities examine data on a drug or vaccine as it becomes available instead of waiting for a complete file at the end. For investors, this can speed up the timeline to approval and reduce uncertainty because regulators assess progress in real time—think of reading and approving chapters of a book as they’re finished rather than waiting for the whole manuscript, which can bring forward potential market access and revenue.

left ventricular ejection fraction medical

"improvement in left ventricular ejection fraction"

Left ventricular ejection fraction (LVEF) is the percentage of blood the heart’s main pumping chamber pushes out with each beat, measured by comparing the volume before and after contraction. Think of it as how much water a pump empties from a tank each cycle — higher percentages mean stronger pumping. Investors care because LVEF is a common clinical measure that affects patient outcomes, market size for treatments, trial success, reimbursement and regulatory decisions in healthcare-related investments.

propensity score-matched technical

"combined with propensity score-matched natural history patients"

A propensity score-matched analysis is a statistical method that pairs individuals from two groups (for example, those who received a treatment and those who did not) who had a similar likelihood of receiving that treatment based on observed characteristics. Like comparing twins who share the same background except for one difference, this approach reduces bias from measurable factors and makes results more comparable, helping investors judge whether reported effects are likely real or driven by differences in the groups.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

$100 million Strategic Transaction Closed

Plans to Submit New Drug Application for Ifetroban in DMD

Top-Line Results Announced for Systemic Sclerosis Trial

NASHVILLE, Tenn., Nov. 10, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company developing new products for rare diseases, announced today its third quarter 2026 financial results and provided a company update. Cumberland has announced its decision to submit a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for ifetroban as a potential treatment for the cardiomyopathy associated with Duchenne muscular dystrophy ("DMD").

The third quarter of 2026 marked Cumberland's first period of operations following the July 1, 2026, closing of its Strategic Transaction with Apotex Health, the largest pharmaceutical company based in Canada. Cumberland's commercial brands and organization were integrated into Apotex's U.S. branded business. The $100 million in proceeds at closing strengthened the company's balance sheet, simplified its business model and allowed Cumberland to concentrate its resources on its clinical pipeline.

"Our first full quarter as a development-focused company has reinforced the value of concentrating our efforts on our clinical pipeline," said A.J. Kazimi, CEO of Cumberland Pharmaceuticals. "Our team and resources are now dedicated to developing new medicines for unmet medical needs. We have the financial strength and the expertise to pursue our new mission, as we work to create lasting value for patients and shareholders."

RECENT COMPANY DEVELOPMENTS INCLUDE:

Plans to File New Drug Application for Ifetroban in DMD

Cumberland announced its decision to submit an NDA to the FDA for ifetroban as a potential treatment for the cardiomyopathy associated with DMD, a rare, fatal genetic neuromuscular disease that results in deterioration of the skeletal, heart and lung muscles. The decision follows a pre-NDA meeting with the FDA this fall. The FDA granted Cumberland's request for a rolling review, which allows completed sections of the application to be submitted for review before the entire application is filed.

The submission will be supported by data from the Phase 2 FIGHT DMD^® trial, which demonstrated a statistically significant 5.4 percentage point improvement in left ventricular ejection fraction (p=0.002) in the high-dose group compared with a control group of placebo-treated patients combined with propensity score-matched natural history patients. Findings also included a reduction in markers of cardiac damage. The NDA submission will also include long-term data from the ongoing open-label extension, preclinical data published in the Journal of the American Heart Association, manufacturing information and a safety database of more than 1,400 subjects across approximately 30 clinical studies.

Through up to 36 months of treatment across the Phase 2 trial and its open-label extension, ifetroban has maintained a favorable safety profile in DMD patients, with no treatment-related serious adverse events or new safety concerns.

There is currently no approved therapy specifically targeting DMD heart disease, the leading cause of death in these patients. Ifetroban has received Orphan Drug, Rare Pediatric Disease and Fast Track designations, and the FDA has conditionally accepted DYSCORBAN^® as the proprietary name for the product. Cumberland has also secured a growing portfolio of patents protecting ifetroban for this DMD heart disease indication.

Top-Line Results from Phase 2 Systemic Sclerosis Trial

Cumberland announced top-line results from its Phase 2a ASSIST-SSc trial evaluating ifetroban in patients with Systemic Sclerosis (SSc), a debilitating autoimmune disease characterized by diffuse fibrosis of the skin and internal organs, with no approved therapy for the underlying condition. Ifetroban was generally well tolerated, with a safety profile consistent with prior experience, and no serious adverse event during the 12-month treatment period was assessed as related to study drug.

As next steps, Cumberland plans to submit the clinical study report to the FDA and complete correlative biomarker studies using specimens collected during the trial, along with cardiac imaging evaluations from patients continuing in the open-label extension. These findings will inform the company's decision on further development of ifetroban in SSc.

New Mission Reflects Focus on Innovation

Following the Strategic Transaction, Cumberland completed a strategic planning process to take a fresh look at who the company is and where it is headed.

The result is a refined mission statement that reflects the company's emphasis on innovation:

Advancing new therapies that address significant unmet medical needs.

The mission guides Cumberland's next chapter as an innovation-focused biopharmaceutical company developing new products for rare diseases. It centers the company's resources and expertise on advancing its clinical-stage pipeline, led by ifetroban, while continuing to build on its experience developing and delivering differentiated medicines for patients.

FINANCIAL RESULTS:

Net Income: During the third quarter of 2026, the revenues and expenses associated with the Strategic Transaction continued to be classified as discontinued operations. Net income for the quarter was $77.8 million, which included the gain on divestiture of the assets associated with the Strategic Transaction, along with the ongoing investment in research and development, supported by the remaining general and administrative expenses.

Balance Sheet: At September 30, 2026, Cumberland had approximately $114 million in total assets, including $80.6 million in cash and cash equivalents. Liabilities totaled $42 million and total shareholders' equity was $73 million as of September 30, 2026.

EARNINGS REPORT CALL:

A conference call will be held today, November 10, 2026, at 4:30 p.m. Eastern Time to provide a company update and discuss the financial results.

The link to register is https://register-conf.media-server.com/register/BI0050c03d0ef44b49b8905264f4232aef. 

Registered participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.

A replay of the call will be available for one year and can be accessed via the Investor Relations page of Cumberland's website or by visiting https://edge.media-server.com/mmc/p/nbwu96yx. 

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is an innovation-focused biopharmaceutical company developing new therapies to address significant unmet medical needs and improve the patient outcomes. The Company is advancing a clinical pipeline of late-stage product candidates across multiple therapeutic areas with significant unmet medical needs.

Cumberland's Phase 2 clinical programs are also evaluating ifetroban in patients with Idiopathic Pulmonary Fibrosis and Cancer Metastasis. Top-line results from a Phase 2 study in patients with Systemic Sclerosis were recently announced.

For more information, please visit www.cumberlandpharma.com. 

FORWARD LOOKING STATEMENTS:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "may," "will," "expect," "plan," "anticipate," "intend," "believe," "estimate," "potential," "continue," "could," "should," "would" and similar expressions, although not all forward-looking statements contain these words. These statements include, among others, statements regarding the timing, content and completion of the NDA submission, including the rolling review; Cumberland's plan to seek approval based on the FIGHT DMD™ trial and natural history data without conducting additional trials; the results of the ongoing open-label extension analyses; regulatory review, approval and labeling; the potential benefits of Orphan Drug, Rare Pediatric Disease, including eligibility for a priority review voucher, and Fast Track designations, which may not be realized; the proprietary name; patent protection and exclusivity; manufacturing; commercialization and market acceptance; the need for additional capital; competition; reliance on third parties; and other ifetroban programs. These statements are based on current assumptions and plans of Cumberland's management and are subject to risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. Important factors that could cause such differences include, among others, the risk that FDA will refuse to file the NDA or will not approve ifetroban; the risk that FDA will not agree with Cumberland's interpretation of the minutes or outcomes of its meetings with FDA; the risk that FDA will require additional trials and data, which could significantly delay or prevent approval and require substantial additional capital; the risk that additional data may not be favorable; Cumberland's ability to meet FDA's other approval requirements, including chemistry, manufacturing and controls requirements; the risk that rolling review will not shorten the review timeline; restrictions that may be placed on the label, if approved; changes in FDA requirements, policies or regulatory pathways; and the risks described under the heading "Risk Factors" in Cumberland's most recent Form 10-K and subsequent Form 10-Q filings, as well as other reports filed with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Cumberland undertakes no obligation to update any forward-looking statement except as required by law.

- MORE  -

CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(Unaudited)
	September 30, 2026		December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents	$         80,581,021		$         11,444,693
Accounts receivable, net	2,132,107		16,944,780
Accounts receivable - TSA, net	10,373,965		—
Receivable from Apotex	10,617,805		—
Inventories, net	29,935		29,935
Prepaid and other current assets	634,174		654,166
Current assets of discontinued operations	191,731		7,986,693
Total current assets	104,560,738		37,060,267
Non-current inventories	42,230		40,879
Property and equipment, net	232,154		264,724
Intangible assets, net	35,471		53,621
Operating lease right-of-use assets	7,188,055		5,781,728
Other assets	1,720,645		2,973,378
Assets of discontinued operations	—		30,649,395
Total assets	$       113,779,293		$         76,823,992
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable	$         16,502,496		$         18,567,546
Payable to Apotex	6,889,538		—
Operating lease current liabilities	521,323		467,774
Pre-close accrued liabilities	—		7,774,143
Other current liabilities	6,462,094		2,855,952
Other current liabilities - TSA	3,954,134		—
Current liabilities of discontinued operations	—		7,079,504
Total current liabilities	34,329,585		36,744,919
Revolving line of credit - long term	—		5,240,733
Operating lease non-current liabilities	4,074,445		4,471,965
Other long-term liabilities	3,200,097		3,626,875
Liabilities of discontinued operations	—		2,195,278
Total liabilities	41,604,127		52,279,770
Equity:
Shareholders' equity:
Common stock—  no par value; 100,000,000 shares authorized; 14,992,812 and 14,956,627 shares issued and outstanding as of September 30, 2026, and December 31, 2025, respectively	51,578,550		51,684,381
Accumulated earnings (deficit)	20,927,415		(26,804,059)
Total shareholders' equity	72,505,965		24,880,322
Noncontrolling interests	(330,799)		(336,100)
Total equity	72,175,166		24,544,222
Total liabilities and equity	$       113,779,293		$         76,823,992

 

CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
(Unaudited)
	Three months ended September 30,				Nine months ended September 30,
	2026		2025		2026		2025
Transition services revenue	$    1,950,000		$       171,821		$    1,950,000		$       719,247
Net revenue	206,356		—		536,665		—
Total revenue	2,156,356		171,821		2,486,665		719,247
Costs and expenses:
Cost of transition services	1,062,266		—		1,062,266		—
Research and development	841,162		646,473		2,379,170		2,178,866
General and administrative	2,182,285		2,376,284		7,128,677		7,244,245
Amortization	7,125		5,586		21,276		17,430
Total costs and expenses	4,092,838		3,028,343		10,591,389		9,440,541
Operating loss	(1,936,482)		(2,856,522)		(8,104,724)		(8,721,294)
Interest income	822,886		131,583		961,802		384,781
Interest expense	(4,604)		(29)		(5,394)		(4,892)
Loss before income taxes	(1,118,200)		(2,724,968)		(7,148,316)		(8,341,405)
Income tax expense	(3,871)		(5,670)		(11,611)		(17,011)
Net loss from continuing operations	(1,122,071)		(2,730,638)		(7,159,927)		(8,358,416)
Discontinued operations:
Income (loss) from discontinued operations	(1,725,098)		781,592		(3,248,722)		6,922,347
Gain on disposal of discontinued operations	81,092,578		—		81,092,578		—
Income tax expense on disposal of discontinued operations	(467,657)		—		(467,657)		—
Net income of discontinued operations	78,899,823		781,592		77,376,199		6,922,347
Net income (loss)	77,777,752		(1,949,046)		70,216,272		(1,436,069)
Net income (loss) at subsidiary attributable to noncontrolling interests	(766)		8,282		(5,301)		11,633
Net income (loss) attributable to common shareholders	$  77,776,986		$   (1,940,764)		$  70,210,971		$   (1,424,436)
Income (loss) per share attributable to common shareholders
- Continuing operations - basic	$           (0.07)		$            (0.18)		$           (0.48)		$            (0.56)
- Discontinued operations - basic	5.26		0.05		5.17		0.46
	$             5.19		$            (0.13)		$             4.69		$            (0.10)
- Continuing operations - diluted	$           (0.07)		$            (0.18)		$           (0.46)		$            (0.56)
- Discontinued operations - diluted	5.14		0.05		5.06		0.46
	$             5.07		$            (0.13)		$             4.60		$            (0.10)
Weighted-average shares outstanding
- basic	14,989,763		14,958,534		14,977,899		14,953,944
- diluted	15,342,174		14,958,534		15,278,850		14,953,944

 

CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
(Unaudited)
	Nine months ended September 30,
	2026		2025
Cash flows from operating activities:
Net income (loss)	$      70,216,272		$       (1,436,069)
Gain on disposal of discontinued operations	(80,624,921)		—
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization expense	101,923		99,324
Amortization of operating lease right-of-use asset	721,984		721,984
Share-based compensation	192,791		236,160
Increase in cash surrender value of life insurance policies over premiums paid	(79,198)		(131,967)
Net changes in assets and liabilities affecting operating activities:
Accounts receivable	1,503,059		1,270,864
Inventories, net	—		101,652
Other current assets and other assets	1,356,318		(192,899)
Operating lease liabilities	(679,803)		(662,118)
Accounts payable and other current liabilities	6,584,369		(2,587,613)
Other long-term liabilities	(426,778)		59,764
Net cash used in operating activities from continuing operations	(1,133,984)		(2,520,918)
Discontinued operations	191,731		7,450,415
Net cash provided by (used in) operating activities	(942,253)		4,929,497
Cash flows from investing activities:
Additions to property and equipment	(48,095)		(97,905)
Investment in cash surrender value of life insurance policies	(42,018)		—
Net (increase) decrease of investment in manufacturing	(1,792,479)		(580,866)
Additions to intangible assets	(5,757)		(807)
Net cash used in investing activities from continuing operations	(1,888,349)		(679,577)
Discontinued operations	99,984,255		(953,582)
Net cash provided by (used in) investing activities	98,095,906		(1,633,159)
Cash flows from financing activities:
Proceeds from ATM offering, net	—		5,266,334
Payments on line of credit	(5,240,733)		(10,035,437)
Exercise of options and purchases of shares from employees	21,725		—
Cash dividend paid	(22,479,497)		—
Payments made in connection with repurchase of common shares	(318,820)		(263,478)
Net cash used in financing activities from continuing operations	(28,017,325)		(5,032,581)
Discontinued operations	—		(1,031,197)
Net cash used in financing activities	(28,017,325)		(6,063,778)
Net increase (decrease) in cash and cash equivalents	69,136,328		(2,767,439)
Cash and cash equivalents at beginning of period	11,444,693		17,964,184
Cash and cash equivalents at end of period	$      80,581,021		$      15,196,745

 

View original content:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-reports-q3-2026-financial-results--company-update-302935555.html

SOURCE Cumberland Pharmaceuticals Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did Cumberland Pharmaceuticals report a profit in Q3 2026?

Cumberland's Q3 profit included an $81,092,578 gain on disposal of discontinued operations associated with the Apotex Health transaction. Total net income was $77,777,752, while continuing operations recorded a $1,122,071 loss.

What did Cumberland's Phase 2 ifetroban trial show for DMD heart disease?

The high-dose group showed a statistically significant 5.4 percentage point improvement in left ventricular ejection fraction, a measure of heart pumping function, versus the combined control group, with p=0.002. Controls combined placebo-treated patients with natural-history patients matched using propensity scores. Findings also included reduced markers of cardiac damage.

What additional evidence will support Cumberland's ifetroban application for DMD heart disease?

The application will include long-term extension data, preclinical data, manufacturing information and safety data alongside the Phase 2 trial results. The safety database covers more than 1,400 subjects across approximately 30 clinical studies. The preclinical data were published in the Journal of the American Heart Association.